Caris Life Sciences, Inc. develops and commercializes AI-enabled precision medicine solutions built around comprehensive molecular profiling, next-generation sequencing and machine learning. The company’s diagnostics and data platform use Whole Genome, Whole Exome and Whole Transcriptome Sequencing, a multimodal clinico-genomic database and high-performance computing to support early detection, diagnosis, monitoring, therapy selection and drug development.
Company announcements commonly address molecular profiling services, clinical therapy selection volume, product launches and regulatory or reimbursement actions for tests such as Caris Assure, Caris MI Clarity and Caris ChromoSeq. Other recurring developments include peer-reviewed validation of Caris AI Insights, Caris Precision Oncology Alliance collaborations, conference presentations and quarterly financial results.
Caris Life Sciences (NASDAQ: CAI) announced a partnership with Everlywell to launch Caris Detect, a forthcoming multi-cancer early detection (MCED) blood assay that uses whole genome sequencing (WGS) and AI-driven analysis to identify molecular signals in blood.
The collaboration will distribute Caris Detect via Everlywell's consumer platform and infrastructure; Caris expects to launch the assay in the first half of 2026. Everlywell cites broad reach, having delivered nearly 1 billion personalized health insights and served 60 million people.
Caris Life Sciences (NASDAQ: CAI) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Caris will present and participate in a Q&A session on Monday, January 12, 2026 at 1:30 PM PT.
Live and replay webcasts will be available on the Investor Relations section of Caris' website at CarisLifeSciences.com. The company is described as a patient-centric AI TechBio and precision medicine firm using whole exome and whole transcriptome sequencing plus AI to build a multimodal clinico-genomic database and computing platform.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge MA, Tokyo and Basel; media and investor contact emails are provided for inquiries.
Caris Life Sciences (NASDAQ: CAI) announced on December 19, 2025 that Providence Swedish Cancer Institute and the Paul G. Allen Research Center joined the Caris Precision Oncology Alliance (Caris POA).
The addition expands the Caris POA to 99 cancer centers, including 45 NCI-designated centers, and gives members access to Caris' multimodal molecular profiling (genomic, transcriptomic, proteomic) and a clinico-genomic database containing matched molecular and outcomes data from hundreds of thousands of cancer patients.
Caris Life Sciences (NASDAQ: CAI) announced a multi-year collaboration and license agreement with Genentech on Dec 16, 2025 to identify and validate novel oncology targets in solid tumors.
Under the deal Caris is eligible to receive $25 million in upfront and near-term payments and up to $1.1 billion in potential research, development, commercial and net sales milestone payments, plus potential tiered royalties on net sales. Caris will leverage its repository of nearly 500,000 solid tumor samples and multimodal molecular and clinical data to support tissue-based target discovery and validation.
Caris Life Sciences (NASDAQ: CAI) will present 19 studies at the San Antonio Breast Cancer Symposium (SABCS) from Dec 9–12, 2025. The research spans seven breast cancer subtypes (HR+/HER2–, HER2+, HER2-low/ultralow/null, triple-negative, invasive lobular, male, metastatic) and reflects multi-omics tumor profiling, whole exome/transcriptome sequencing, IHC, and AI-driven signatures.
Two studies are selected for oral/rapid oral presentation focusing on multimodal AI for recurrence prediction and late distant recurrence risk. The 19 studies involve 40+ collaborating institutions and Caris Precision Oncology Alliance (Caris POA), which includes 98 centers with 45 NCI-designated cancer centers. Abstracts and poster summaries will be available onsite at Caris booth #209 and later on the company website.
Caris Life Sciences (NASDAQ: CAI) announced on Dec 2, 2025 that the UAMS Winthrop P. Rockefeller Cancer Institute joined the Caris Precision Oncology Alliance (Caris POA).
The Caris POA now includes 98 centers, including 45 NCI‑designated cancer centers. Members gain access to Caris' multimodal molecular profiling (genomic, transcriptomic, proteomic) and a large matched clinico‑genomic database containing data from hundreds of thousands of cancer patients with tens of billions of data points per patient to support biomarker‑driven research and trial matching.
Caris Life Sciences (NASDAQ: CAI) announced selection of 15 physician-scientists for the 2025/2026 Caris Precision Oncology Alliance Fellows Forum, a competitive two-year program offering mentorship, hands-on training and access to Caris' CODEai database covering >484,000 patients and over one million data points per patient.
Fellows will receive direct mentorship, collaborative research across 97 cancer institutions, structured education, monthly workshops, lab tours in Phoenix, and participation at the Caris POA Summit at the ASCO Annual Meeting.
Caris Life Sciences (NASDAQ: CAI) will attend multiple investor conferences in Q4 2025 and is offering investor meetings on specific dates. Wolfe Research 7th Annual Healthcare Conference (New York): investor meetings on November 18, 2025. Citi 2025 Global Healthcare Conference (Miami): investor meetings on December 3, 2025. Evercore 8th Annual Healthcare Conference (Miami): investor meetings on December 4, 2025.
Investors and analysts can request meetings by contacting IR@CarisLS.com. Caris is headquartered in Irving, Texas, and describes itself as a patient‑centric AI TechBio company focused on comprehensive molecular profiling and precision medicine solutions.
Caris Life Sciences (Nasdaq: CAI) reported third quarter 2025 results and raised full-year guidance on Nov 5, 2025. Q3 revenue was $216.8M, up 113.4% YoY, driven by molecular profiling services. Management reported net income $24.3M, adjusted EBITDA $51.2M, and gross margin 68.0% (up 2,432 bps). Q3 clinical case volume totaled 50,763 (up 18.2%). Cash provided by operations was $62.4M and free cash flow $55.3M. Company raised 2025 revenue guidance to $720–$730M, implying 75–77% YoY growth.
Caris Life Sciences (NASDAQ: CAI) announced validation of TET2 clonal hematopoiesis (CH) as a biomarker associated with improved response to immune checkpoint inhibitor (ICI) therapy in solid tumors.
The study, led at MD Anderson and published in Cancer Cell, combined laboratory models with analysis of Caris' clinico-genomic database covering ~36,000 NSCLC and >25,000 colorectal cancer patients to show TET2-CH links to enhanced macrophage antigen presentation and better ICI outcomes.
The company highlights potential future use of CH to guide therapy selection while noting these findings inform but do not guarantee changes to clinical practice.